Press & News

People are different and so is their cancer, patients should be treated individually.

2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021.

October 12, 2021

IR

Regulatory

2cureX AB (publ) will hold a Live Strategy Update session on 12th October at 13:00 (CET). Presentations will be followed by a Questions & Answers discussion moderated by Redeye’s Equity Analyst, Erik Nordström.

2cureX’s CEO Fernando Andreu, together with Ole Thastrup (CSO), Pia van der Zee (VP of Marketing) and Jesper Floyd Kristiansen (VP of Sales) will present 2cureX’s overall strategy based on three pillars: IndiTreat Technology, Product Portfolio and Sales and Marketing. The presentations will highlight the main topics in each of the three areas, as well as the goals to be achieved in 2022. 2cureX is fully focused on the rollout of its first IndiTreat® products in Europe through the expansion of its distributor network. The company plans to be present in 20 European countries by the end of 2022 and have 30 hospitals using IndiTreat®. The company will also unveil plans to launch one additional metastatic colorectal cancer test in December 2021 and one more in 2022. A broad market penetration in terms of number of hospitals is seen as the key factor to drive sales growth.

We encourage present and potential future shareholders to listen to the Strategy Update to receive the latest news and plans going forward.

Link to Strategy Update webcast:

https://www.redeye.se/events/818830/strategy-update-2curex

Link to registration:

https://www.lyyti.fi/reg/Strategy_Update_2cureX

The presentation will be held in English.